On 27 February 2017, orphan designation (EU/3/17/1830) was granted by the European Commission to Voisin Consulting S.A.R.L., France, for 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (also known as PQR309) for the treatment of diffuse large B-cell lymphoma.
This medicine is now known as bimiralisib.
The sponsorship was transferred to SFL Pharmaceuticals Deutschland GmBH, Germany in June 2021
Treatment of diffuse large B-cell lymphoma
|Date of designation||
|Orphan designation status||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.